Last reviewed · How we verify
Metformin & Entecavir — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Metformin & Entecavir (Metformin & Entecavir) — Fu-Sheng Wang.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metformin & Entecavir TARGET | Metformin & Entecavir | Fu-Sheng Wang | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metformin & Entecavir CI watch — RSS
- Metformin & Entecavir CI watch — Atom
- Metformin & Entecavir CI watch — JSON
- Metformin & Entecavir alone — RSS
Cite this brief
Drug Landscape (2026). Metformin & Entecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-entecavir. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab